Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Celcuity Inc (CELC)

Celcuity Inc (CELC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 515,874
  • Shares Outstanding, K 30,453
  • Annual Sales, $ 0 K
  • Annual Income, $ -63,780 K
  • 60-Month Beta 0.78
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.20
Trade CELC with:

Options Overview Details

View History
  • Implied Volatility 64.86% ( -5.40%)
  • Historical Volatility 66.94%
  • IV Percentile 37%
  • IV Rank 25.60%
  • IV High 154.93% on 06/13/23
  • IV Low 33.87% on 06/21/23
  • Put/Call Vol Ratio 0.10
  • Today's Volume 11
  • Volume Avg (30-Day) 47
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 578
  • Open Int (30-Day) 621

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.70
  • Number of Estimates 4
  • High Estimate -0.59
  • Low Estimate -0.78
  • Prior Year -0.55
  • Growth Rate Est. (year over year) -27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.93 +1.44%
on 04/25/24
22.19 -27.17%
on 03/28/24
-1.64 (-9.21%)
since 03/25/24
3-Month
13.74 +17.61%
on 02/21/24
22.19 -27.17%
on 03/28/24
+1.52 (+10.38%)
since 01/25/24
52-Week
8.39 +92.63%
on 10/09/23
22.19 -27.17%
on 03/28/24
+6.67 (+70.28%)
since 04/25/23

Most Recent Stories

More News
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Celcuity Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

CELC : 16.15 (-4.66%)
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer

MINNEAPOLIS, MN / ACCESSWIRE / July 18, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced...

CELC : 16.15 (-4.66%)
Wall Street Analysts Think Celcuity, Inc. (CELC) Could Surge 359%: Read This Before Placing a Bet

The mean of analysts' price targets for Celcuity, Inc. (CELC) points to a 359.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

CELC : 16.15 (-4.66%)
Can Celcuity, Inc. (CELC) Climb 462% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 461.9% in Celcuity, Inc. (CELC). While the effectiveness of this highly sought-after metric is questionable, the...

CELC : 16.15 (-4.66%)
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences

MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients...

CELC : 16.15 (-4.66%)
Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates

- Entered into $100 Million Private Placement Agreement - Finalized pivotal Phase 3 trial design for gedatolisib - Received FDA Fast Track designation for gedatolisib in HR+/HER2- advanced breast cancer...

CELC : 16.15 (-4.66%)
Celcuity Inc. Announces $100 Million Private Placement

Proceeds to Advance Clinical Development of Gedatolisib Including Forthcoming Phase 3 Clinical Study (VIKTORIA-1) MINNEAPOLIS, MN / ACCESSWIRE / May 16, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage...

CELC : 16.15 (-4.66%)
Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call

MINNEAPOLIS, MN / ACCESSWIRE / May 9, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients...

CELC : 16.15 (-4.66%)
Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences

MINNEAPOLIS, MN / ACCESSWIRE / April 5, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients...

CELC : 16.15 (-4.66%)
Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates

- Finalized pivotal Phase 3 trial design following formal meetings with FDA - Received FDA Fast Track designation for gedatolisib in HR+/HER2- metastatic breast cancer - Presented updated Phase 1b data...

CELC : 16.15 (-4.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's...

See More

Key Turning Points

3rd Resistance Point 17.53
2nd Resistance Point 17.40
1st Resistance Point 17.17
Last Price 16.15
1st Support Level 16.81
2nd Support Level 16.68
3rd Support Level 16.45

See More

52-Week High 22.19
Fibonacci 61.8% 16.92
Last Price 16.15
Fibonacci 50% 15.29
Fibonacci 38.2% 13.66
52-Week Low 8.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar